Literature DB >> 29896403

Evaluation of tumor-free distance and depth of myometrial invasion as prognostic factors in endometrial cancer.

Raoudha Doghri1, Salma Chaabouni1, Yoldez Houcine1, Lamia Charfi1, Nadia Boujelbene1, Maha Driss1, Karima Mrad1.   

Abstract

The aim of the study was to investigate whether the tumor free distance (TFD), which is the distance in millimeters between the deepest point of invasion and the serosal surface, and absolute depth of invasion (DMI), the distance in millimeters between the endomyometrial junction and the deepest point of myometrial invasion, are useful in surgical staging and in predicting prognosis. The present study retrospectively analyzed 62 cases of endometrial carcinoma with complete surgical staging, carried out over a 4 and half-year period (January 2003 to June 2007). All surgicopathological findings including surgical stages, histological type and grade, myometrial invasion, lymphovascular space invasion, cervical and adnexal involvement, and lymph node metastasis were abstracted from medical records and pathological reports. Univariate and multivariate analyses were performed comparing TFD, DMI and the percentage of mypmetrial invasion (MI) with established prognostic factors. A total of 62 patients were included in the study. A total of 52 (84%) had endometrioid carcinomas and 31 patients (60%) had grade 1 cancer. The deepest MI was <50% in 32 patients (52%). Median DMI was 2.7 mm (range 0-15 mm). Median TFD was 3 mm (range 0-19 mm). There was lymphovascular space invasion (LVSI) in 11 patients (17.5%), cervical involvement in 11 patients (17.5%), extra-uterine extension in 9 cases (14%) and lymph node metastasis in 12 patients (22%). It was demonstrated that 50% MI was significantly associated with prognostic factors (cervical involvement, type 2 carcinomas and LVSI, and was a significant predictor of the 5-year overall survival rate and recurrence-free survival (P=0.05, P=0.01). No significant association was observed between DMI and TFD with clinicopathological parameters and survival rates. The importance of DMI in predicting recurrence of disease was observed to be highest in terms of sensitivity and specificity. The cut-off value with the highest sensitivity and specificity crossing the receive operating characteristic curve was calculated to be 3 mm for DMI and 2.5 mm for TFD. The results indicate that DMI is a superior predictive factor of recurrence of the disease compared with TFD. However, further studies are required in order to prove the prognostic usefulness of these parameters and then to improve management of endometrial cancer.

Entities:  

Keywords:  cancer staging; endometrium cancer; myometrial invasion; prognosis; tumor-free distance

Year:  2018        PMID: 29896403      PMCID: PMC5995060          DOI: 10.3892/mco.2018.1629

Source DB:  PubMed          Journal:  Mol Clin Oncol        ISSN: 2049-9450


  14 in total

1.  Evaluation of tumor-free distance and depth of myometrial invasion as prognostic factors for lymph node metastases in endometrial cancer.

Authors:  Srinivas Kondalsamy-Chennakesavan; Stijn van Vugt; Karen Sanday; Jim Nicklin; Russell Land; Lewis Perrin; Alex Crandon; Andreas Obermair
Journal:  Int J Gynecol Cancer       Date:  2010-10       Impact factor: 3.437

2.  Tumour-free distance from serosa is a better prognostic indicator than depth of invasion and percentage myometrial invasion in endometrioid endometrial cancer.

Authors:  S Chattopadhyay; K A Galaal; A Patel; A Fisher; A Nayar; P Cross; R Naik
Journal:  BJOG       Date:  2012-07-17       Impact factor: 6.531

3.  Low-grade, low-stage endometrioid endometrial adenocarcinoma: a clinicopathologic analysis of 324 cases focusing on frequency and pattern of myoinvasion.

Authors:  Charles M Quick; Taymaa May; Neil S Horowitz; Marisa R Nucci
Journal:  Int J Gynecol Pathol       Date:  2012-07       Impact factor: 2.762

4.  Absolute depth of myometrial invasion in endometrial cancer is superior to the currently used cut-off value of 50%.

Authors:  Y P Geels; J M A Pijnenborg; S H M van den Berg-van Erp; M P M L Snijders; J Bulten; L F A G Massuger
Journal:  Gynecol Oncol       Date:  2013-02-17       Impact factor: 5.482

5.  Tumor size, depth of invasion, and histologic grade as prognostic factors of lymph node involvement in endometrial cancer: a SEER analysis.

Authors:  Roberto Vargas; J Alejandro Rauh-Hain; Joel Clemmer; Rachel M Clark; Annekathryn Goodman; Whitfield B Growdon; John O Schorge; Marcela G Del Carmen; Neil S Horowitz; David M Boruta
Journal:  Gynecol Oncol       Date:  2014-02-16       Impact factor: 5.482

6.  Is there a prognostic difference between depth of myometrial invasion and the tumor-free distance from the uterine serosa in endometrial cancer?

Authors:  Jaina Lindauer; Jeffrey M Fowler; Tom P Manolitsas; Larry J Copeland; Lynne A Eaton; Nilsa C Ramirez; David E Cohn
Journal:  Gynecol Oncol       Date:  2003-12       Impact factor: 5.482

7.  Prospective evaluation of prognostic significance of the tumor-free distance from uterine serosa in surgically staged endometrial adenocarcinoma.

Authors:  Katherine V Schwab; David M O'Malley; Jeffrey M Fowler; Larry J Copeland; David E Cohn
Journal:  Gynecol Oncol       Date:  2008-10-19       Impact factor: 5.482

8.  The risk of lymph node metastasis based on myometrial invasion and tumor grade in endometrioid uterine cancers: a multicenter, retrospective Korean study.

Authors:  Kwang-Beom Lee; Kyung-Do Ki; Jong-Min Lee; Jae-Kwan Lee; Jae Weon Kim; Chi-Heum Cho; Seok-Mo Kim; Sang-Yoon Park; Dae-Hoon Jeong; Ki-Tae Kim
Journal:  Ann Surg Oncol       Date:  2009-05-30       Impact factor: 5.344

9.  Reproducibility of measurement of myometrial invasion in endometrial carcinoma.

Authors:  Louis J M van der Putten; Koen van de Vijver; Carla Bartosch; Ben Davidson; Sonia Gatius; Xavier Matias-Guiu; W Glenn McCluggage; Gemma Toledo; Anneke A M van der Wurff; Johanna M A Pijnenborg; Leon F A G Massuger; Johan Bulten
Journal:  Virchows Arch       Date:  2016-10-27       Impact factor: 4.064

Review 10.  Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review, and meta-analysis.

Authors:  P Blake; Ann Marie Swart; J Orton; H Kitchener; T Whelan; H Lukka; E Eisenhauer; M Bacon; D Tu; M K B Parmar; C Amos; C Murray; W Qian
Journal:  Lancet       Date:  2008-12-16       Impact factor: 79.321

View more
  2 in total

1.  Improving Risk Assessment for Metastatic Disease in Endometrioid Endometrial Cancer Patients Using Molecular and Clinical Features: An NRG Oncology/Gynecologic Oncology Group Study.

Authors:  Yovanni Casablanca; Guisong Wang; Heather A Lankes; Chunqiao Tian; Nicholas W Bateman; Caela R Miller; Nicole P Chappell; Laura J Havrilesky; Amy Hooks Wallace; Nilsa C Ramirez; David S Miller; Julie Oliver; Dave Mitchell; Tracy Litzi; Brian E Blanton; William J Lowery; John I Risinger; Chad A Hamilton; Neil T Phippen; Thomas P Conrads; David Mutch; Katherine Moxley; Roger B Lee; Floor Backes; Michael J Birrer; Kathleen M Darcy; George Larry Maxwell
Journal:  Cancers (Basel)       Date:  2022-08-23       Impact factor: 6.575

2.  Prediction of lymphovascular space invasion in patients with endometrial cancer.

Authors:  Sang Il Kim; Joo Hee Yoon; Sung Jong Lee; Min Jong Song; Jin Hwi Kim; Hae Nam Lee; Gyul Jung; Ji Geun Yoo
Journal:  Int J Med Sci       Date:  2021-06-01       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.